Lexeo- Message to the Community

Message to the Friedreich Ataxia Community October 7, 2025 Dear Advocacy Partners and FA community members, This morning, we were pleased to share positive interim clinical data for LX2006, our investigational gene therapy, that includes both cardiac and neurological outcome measures. LX2006 (AAVrh10hFXN) is currently being studied in the Lexeo-sponsored...

Continue reading

2025-Projects focusing on Friedreich’s ataxia in partnership with MDC

Thanks to yous upport and our partnership with Muscular Dystrophy Canada, we have funded two projects focused on Friedreich Ataxia (FA) this year ! We are thrilled to support clinical and translational research projects that focus on managing symptoms, healthcare assessments, understanding diagnosis and disease progression, enhancing care, discovering new...

Continue reading

Finalization of the Project: Creation of an Open Scientific Repository of Stem Cells Derived from Individuals with ARCA1-type Ataxia

The Ataxia Canada Foundation thanks CDPQ for the financial support provided to the research. This project aimed to reprogram patient-derived cells into induced pluripotent stem cells (iPSC) for the study of ARCA1, a disease for which there is a significant lack of representative cellular models. Impact of this Research: Specific...

Continue reading

New Gene Therapy Study in Friedreich’s Ataxia (FA) Sponsored by LEXEO Therapeutics, Inc

The study is being conducted with multiple sites in the United States and Canada seeking to recruit approximately 9 participants aged 18-40 with a diagnosis of FA-associated cardiomyopathy. The study will be conducted by Dr. Antoine Duquette at the CHUM in Montreal. The choice of Montreal as a site reflects...

Continue reading